POTENTIAL NEW CANCER THERAPIES ON THE HORIZON

Investigational product candidates in the Dendreon pipeline include:

• Lapuleucel-T—an active cellular immunotherapy (ACI) targeted to the HER 2/neu receptor in development for bladder, breast, ovarian, and colon cancer.
• D-3263, HCl—a small molecule compound that activates the ion channel receptor TRPM8 (also known as TRPP8) in clinical development for the potential treatment of patients with solid tumors.

Dendreon has also in-licensed 2 additional antigen targets: carbonic anhydrase IX (CA-9) and carcinoembryonic antigen (CEA), for the development of ACI candidates. Product candidates targeted at CA-9 are in preclinical development for the potential treatment of kidney, colon, and cervical cancer. Product candidates targeted at CEA are in preclinical development for the treatment of breast, lung, and colon cancer.